Article By:
ChinaBio® Today
Saturday, January 13, 2018 6:23 PM EDT
Hua Medicine of Shanghai expects to spend $200 million over the next three years on its novel oral diabetes 2 treatment, dorzagliatin. The company will raise additional capital for the effort and then IPO, possibly in Hong Kong or the US.